November 9-11, 2023

European Charcot Foundation

Baveno, Italy

An Evidence-Based Global MS Patient Charter Created by a Multi-stakeholder Alliance

Wiendl H et al.
Poster: 046

Remibrutinib Ameliorates CNS Autoimmune Disease - Insights From EAE

Cenni B et al.
Poster: 042

Remibrutinib Inhibits Neuroinflammation Driven by B cells and Myeloid Cells in EAE

Nuesslein-Hildesheim B et al.
Poster: 043

Phase 3 REMODEL I/II Trials: Efficacy, Safety and Tolerability of Remibrutinib in RMS

Wiendl H et al.
Poster: 044

Remibrutinib’s Safety Across Immune-Mediated Diseases Supports Development in MS

Montalban X et al.
Poster: 047
Cookie Settings